Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phthalic Acid SCHEMBL4351658 | 0.94 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL1319085 | 0.94 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL198843 | 0.94 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL18730184 | 0.94 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL109123 | 0.94 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL848649 | 0.94 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL5604206 | 0.94 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL8736352 | 0.94 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL2164112 | 0.94 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL7519717 | 0.94 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDCA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110537394-B | Printed circuit nanoweb manufacturing method and printed circuit nanoweb | 阿莫绿色技术有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-11324123-B2 | Printed circuit nanofiber web manufacturing method | AMOGREENTECH CO., LTD (KR) | 2022-05-03 | — | — | US | disclosed |
| US-11013730-B1 | Composition comprising selenazol or thiazalone derivatives and silver and method of treatment therewith | THIOREDOXIN SYSTEMS AB (SE) | 2021-05-25 | — | — | US | disclosed |
| US-20200137891-A1 | PRINTED CIRCUIT NANOFIBER WEB MANUFACTURING METHOD, PRINTED CIRCUIT NANOFIBER WEB MANUFACTURED THEREBY, AND ELECTRONIC DEVICE EMPLOYING SAME | AMOGREENTECH CO., LTD (KR) | 2020-04-30 | — | — | US | disclosed |
| US-10058542-B1 | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith | THIOREDOXIN SYSTEMS AB (SE) | 2018-08-28 | — | — | US | disclosed |
| US-8425880-B1 | Metal-containing materials for treatment of bacterial conditions | NUCRYST PHARMACEUTICALS CORP. (CA) | 2013-04-23 | — | — | US | disclosed |
| US-20130095184-A1 | Metal-Containing Materials for Treatment of Bacterial Conditions | NUCRYST PHARMACEUTICALS CORP. (CA) | 2013-04-18 | — | — | US | disclosed |
| EP-2043611-A2 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | Nucryst Pharmaceuticals Corp. (CA) | 2009-04-08 | — | — | EP | disclosed |
| WO-2009014781-A2 | METAL-CONTAINING MATERIALS FOR TREATMENT OF BACTERIAL CONDITIONS | NUCRYST PHARMACEUTICALS CORP. (CA) | 2009-01-29 | — | — | WO | disclosed |
| US-20080050452-A1 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS | 2008-02-28 | — | — | US | disclosed |
| US-20080044491-A1 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS | 2008-02-21 | — | — | US | disclosed |
| US-20080014278-A1 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS | 2008-01-17 | — | — | US | disclosed |
| US-20080014247-A1 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS | 2008-01-17 | — | — | US | disclosed |
| WO-2008005705-A2 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS CORP. (CA) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11013730-B1 | Composition comprising selenazol or thiazalone derivatives and silver and method of treatment therewith | SELENOI, TST, SCLY | ALDH1A1 1712/4885KDM4E 4710/4885HPGD 1567/4885 |
| US-10058542-B1 | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith | SELENOI, TST, GSS | ALDH1A1 1842/4885KDM4E 4515/4885HPGD 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.